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Neuropeptide W, an endogenous NPBW1
and NPBW2 ligand, produced an analgesic
effect via activation of the descending
pain modulatory system during a rat
formalin test
Shingo Nakamura1, Takahiro Nonaka1, Koji Yoshida1,
Toshihiko Yamada1, and Tatsuo Yamamoto1
Abstract
Neuropeptide W (NPW) messenger ribonucleic acid (mRNA) and NPBW1 and/or NPBW2 mRNA are expressed in the
descending pain inhibitory system. In the present study, we examined whether NPW microinjected into the descending pain
inhibitory system, such as the periaqueductal gray (PAG), locus coeruleus (LC), and rostral ventromedial medulla (RVM),
produces an analgesic effect using a rat formalin test. Microinjections of NPW into the PAG ipsilateral and contralateral to
the formalin-injected side, LC ipsilateral and contralateral to the formalin-injected side, and RVM produced an analgesic
effect. In the RVM study, the analgesic effect was antagonized by WAY100135, a 5-HT1A antagonist, and enhanced by
prazosin, an a1 antagonist, and SB269970, a 5-HT7 antagonist. Naloxone, an opioid antagonist, also antagonized the
effect of NPW in the RVM study. In the ipsilateral LC study, the analgesic effect was antagonized by WAY100135, idazoxan,
an a2 antagonist, and naloxone and was enhanced by prazosin and SB269970. In the contralateral LC study, the analgesic
effect was antagonized by prazosin, idazoxan, SB269970, and naloxone. The analgesic effect was antagonized by WAY100135,
SB269970, idazoxan, and naloxone in the ipsilateral and contralateral PAG studies. These findings strongly suggest that
NPBW1/W2 activation by NPW microinjection into the RVM, LC, and PAG affect the descending pain modulatory system
and produce anti-nociceptive and pro-nociceptive effects in the rat formalin test.
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Opioid-somatostatin-like receptor genes, including
NPBW1 and NPBW2 (previously known as GPR7 and
GPR8, respectively1), were first cloned in 1995 as orphan
receptors.2 NPBW1 and NPBW2 share 70% nucleotide
and 64% amino acid identities.3 Neuropeptide B (NPB)
and neuropeptide W (NPW) have been identified as
endogenous ligands for NPBW1 and NPBW2.4,5 NPW
has two isoforms, NPW23 and NPW30, which are 23
and 30 amino acids in length, respectively. It has been
reported that NPB mainly activates NPBW1, whereas
NPW stimulates both receptors with similar potency.6
It has been reported that the NPB/NPW signaling
system has several physiological functions, including
regulation of feeding activity, neuroendocrine functions
with central regulation, energy homeostasis, autonomic
regulation, activation of the stress axis, pain processing,
and emotion-related autonomic and neuroendocrine
responses.7 Concerning pain processing, NPB gene
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knockout mice demonstrate hyperalgesia in response to
inflammatory pain.8 Moreover, we have previously
reported that the intrathecal (IT) administration of
either NPW or NPB produced an analgesic effect in
both rat inflammatory and neuropathic pain models
and that intracerebroventricular (ICV) injections of
either NPW or NPB had no effect on a rat neuropathic
pain model.9,10 These findings suggest that the role of
NPBW1/W2 and the NPW/NPB system in spinal pain
transmission are different from their role in supra-spinal
pain transmission.
In the brain, NPW mRNA and/or NPBW1 mRNA
has been reported to be expressed in the periaqueductal
gray (PAG), pons, and medulla oblongata.6 Moreover,
NPB/NPW binding was observed in the locus coeruleus
(LC)11and PAG.1 The PAG influences descending pain
modulation through its reciprocal connections with the
rostral ventromedial medulla (RVM).12 The RVM,
located in the medulla oblongata, plays an important
role in the spinal serotonergic modulation of pain. The
LC acted as the center of a descending noradrenergic
pain modulatory system.12
In the present study, to clarify the role of NPBW1/W2
and the NPW system in the descending pain modulatory
system, we investigated the effects of microinjections of
NPW into the RVM, LC, and PAG on pain modulation
in the rat formalin test, an inflammatory pain model.
Methods
This study was performed according to a protocol
approved by the Institutional Animal Care Committee
of Kumamoto University, Kumamoto, Japan. Male
Sprague-Dawley rats (250–300 g; Japan SLC, Inc.,
Shizuoka, Japan) were housed individually, maintained
on a 12 h dark-light cycle, and provided food and water
ad libitum. The animals were handled on arrival and
housed for at least three days before catheter implanta-
tion. The animals were euthanized immediately after the
behavioral study.
RVM, LC, and PAG cannula placements
Injection cannulae were implanted into the RVM, LC,
and PAG under isoflurane anesthesia. The rats were
placed in a stereotaxic apparatus (Kopf Model 900,
David Kopf Instruments, CA). Stainless steel 26G thin
wall guide cannulae (C315G, Plastics One, VA) were
stereotaxically implanted into the RVM, LC, and PAG
through a burr hole (RVM: AP: 11.0mm, L: 0.0mm,
H: 10.1mm from bregma; LC: AP: 10.0mm, L:
1.4mm, H: 7.2mm from bregma; PAG: AP:
7.6mm, L: 0.8mm, H: 5.0mm from bregma).
Guide cannulae were affixed to the skull with stainless
steel screws and cranioplastic cement.
The formalin test was performed seven days after the
cannula implantation. All animals displayed normal
feeding and drinking behaviors postoperatively. Rats
showing neurological deficits after cannula implantation
were not included in the study.
After the experiment, 0.5 ll of India ink was injected
through the internal cannula after the rats were eutha-
nized. The brains were fixed with paraformaldehyde,
and coronal tissue sections were Nissl-stained to confirm
the proper injection site. Only rats whose microinjection
site was located within the intended nucleus were includ-
ed in the results.
Drugs and injection. Drugs were dissolved in saline.
NPW30 (molecular weight¼ 3559) was purchased from
the Peptide Institute Inc. (Osaka, Japan). WAY100135,
a 5-HT1A receptor antagonist, SB269970, a 5-HT7 recep-
tor antagonist, prazosin, an a-1 adrenergic receptor
antagonist, idazoxan, an a-2 adrenergic receptor antag-
onist, and naloxone, an opioid receptor antagonist, were
purchased from Sigma-Aldrich (MO).
NPW30 was administered into the RVM, LC, or
PAG at a total volume of 0.5 lL for 60 s using a micro-
syringe pump (EP-60, EICOM, Japan) and a 30G stain-
less steel internal cannula (C315G, Plastics One, VA)
was connected via a polyethylene tube to a 10 lL
Hamilton syringe.
In our preliminary study, we found that 1 lg of
NPW30 microinjected into the RVM (p> 0.7) and con-
tralateral PAG (p> 0.5) had no analgesic effect as com-
pared with saline-treated rats when injected 10min
before the formalin injection. In the ipsilateral LC
study, the analgesic effect in the NPW30 1 lg treated
rats was the same as that of NPW30 5 lg treated rats
(p> 0.05) when injected 10min before the formalin
injection. The analgesic effect of 1 lg of NPW30 was
less than that of 5 lg of NPW30 in the contralateral
LC (p< 0.001) and the ipsilateral LC study (p< 0.001)
when injected 10min before the formalin injection.
Therefore, we decided that 5lg of NPW30 should be
injected directly into the RVM, LC contralateral or ipsi-
lateral to the formalin-injected side, and PAG contralat-
eral or ipsilateral to the formalin-injected side 10min
before the formalin injection into the footpad. To test
the mechanisms of action of NPW30, one of the follow-
ing drugs was injected 10min before the injection of
NPW30: WAY100135 (46 lg/10 lL, intrathecal [IT]),
SB269970 (10lg/10 ll, IT), prazosin (25 lg/10 lL, IT),
idazoxan (30lg/10 lL, IT), or naloxone (1 mg/kg, intra-
peritoneal [IP]). The doses of WAY100135, SB269970,
prazosin, idazoxan, and naloxone were determined
based on previous reports.13–16 Idazoxan, prazosin,
WAY100135, and SB269970 were injected via the L5-
L6 intervertebral space under 2% isoflurane anesthesia
using a 30G needle.
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Formalin test. In the formalin test, 50 lL of 5% formalin
was injected subcutaneously into the dorsal surface of
the hind paw with a 26G needle under brief isoflurane
anesthesia. Within 1min after the formalin injection,
spontaneous flinching of the injected paw was observed.
Flinching was readily discriminated as a rapid and brief
withdrawal or flexion of the injected paw. This pain-
related behavior was quantified by counting the
number of flinches for 1min periods at 5min intervals,
0–60min after the injection. Two phases of spontaneous
flinching behavior were observed: an initial acute phase
(phase 1: during the first 6min after formalin injection)
and a prolonged tonic phase (phase 2: beginning approx-
imately 10min after formalin injection). The phase 1
response is mediated by the direct stimulation of noci-
ceptors by formalin, and the phase 2 response is medi-
ated by the inflammatory response induced by formalin.
Statistical analysis. The time-response data are presented
as the mean flinches SEM permin for the periods
between 1–2min and 5–6min after the formalin treat-
ment and then for 1min periods at 5min intervals up
to 60min. The data from the phase 1 (0–6min) and
phase 2 (10–60min) observations were analyzed sepa-
rately. The effects of NPW30 on formalin-evoked
flinches during phase 1 and phase 2 were compared
with those of saline using a two-way analysis of variance
(ANOVA). For multiple comparisons, the Holm-Sidak
method was used. In the antagonist study, a two-way
ANOVA was also used. A p-value of <0.05 was consid-
ered statistically significant.
Results
In saline-treated control rats, the subcutaneous injection
of formalin resulted in a highly reliable biphasic display
of flinching of the injected paw, and this behavior was
comparable to that previously reported.17
The injection sites in the RVM, LC, and PAG are
shown in Figure 1. India ink (0.5 lL) injected through
the internal cannula spread to the RVM, LC, and PAG.
Effects of NPW30 injected into the RVM (Figure 2). NPW30
treatment (n¼ 9) decreased the phase 2 flinching instan-
ces (p< 0.001), but not the phase 1 flinching instances
(p> 0.05) as compared with the saline-treated rats
(n¼ 10). The phase 2 depressant effect of NPW30 was
significantly antagonized by IP naloxone (n¼ 8,
p< 0.001) and IT WAY100135 (n¼ 5, p< 0.001). The
phase 2 depressant effect of NPW30 was significantly
enhanced by IT prazosin (n¼ 4, p< 0.001), IT idazoxan
(n¼ 8, p< 0.01), and IT SB269970 (n¼ 5, p< 0.05).
Effects of NPW30 injected into the LC
Ipsilateral LC (Figure 3). NPW30 treatment (n¼ 9)
decreased phase 1 (p< 0.005) and phase 2 (p< 0.001)
flinching instances as compared with the saline-treated
rats (n¼ 7). The phase 2 depressant effect of NPW30
was significantly antagonized by IP naloxone (n¼ 8,
p< 0.05). IT prazosin enhanced the phase 2 depressant
effect of NPW30 (n¼ 4, p< 0.001). IT idazoxan (n¼ 8)
significantly antagonized the phase 2 depressant effect of
NPW30 (p< 0.01) and enhanced the phase 1 depressant
effect (p< 0.05). The IT WAY100135 significantly
antagonized the phase 2 (n¼ 5, p< 0.05) depressant
effect of NPW30. IT SB269970 significantly enhanced
the phase 2 (n¼ 5, p< 0.05) depressant effect of NPW30.
Contralateral LC (Figure 4). NPW30 treatment
(n¼ 12) decreased phase 1 (p< 0.001) and phase 2
(p< 0.001) flinching instances as compared with the
saline-treated rats (n¼ 10).The phase 1 depressant
effect of NPW30 was significantly antagonized by IP
naloxone (n¼ 11, p< 0.005) and IT SB269970 (n¼ 5;
p< 0.05). The phase 2 depressant effect of NPW30 was
significantly antagonized by IP naloxone (n¼ 11,
p< 0.001), IT prazosin (n¼ 4, p< 0.001), IT idazoxan
(n¼ 17, p< 0.001), and IT SB269970 (p< 0.001).
Effects of NPW30 injected into the PAG
Ipsilateral PAG (Figure 5). NPW30 treatment (n¼ 7)
decreased phase 1 (p< 0.05) and phase 2 (p< 0.001)
flinching instances as compared with the saline-treated
rats (n¼ 10).The phase 1 depressant effect of NPW30
Figure 1. Injection sites in the RVM, LC, and PAG. The spread of 0.5 ll of India ink was injected through the internal cannulae. Nissl-
stained sections were used to confirm the injection sites. RVM, LC, and PAG were located within the regions stained by India ink. Scale bar:
200 lm.
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was significantly antagonized by IT WAY100135 (n¼ 5,
p< 0.05). The phase 2 depressant effect of NPW30 was
significantly antagonized by IP naloxone (n¼ 8,
p< 0.001), IT idazoxan (n¼ 8, p< 0.001), IT
WAY100135 (p< 0.001), and IT SB269970 (n¼ 5.
p< 0.001).
Contralateral PAG (Figure 6). NPW30 treatment
(n¼ 17) decreased phase 1 (p< 0.05) and phase 2
(p< 0.001) flinching instances as compared with the
saline-treated rats (n¼ 14). The phase 1 depressant
effect of NPW30 was significantly antagonized by IT
WAY100135 (n¼ 7, p< 0.05). The phase 2 depressant
effect of NPW30 was significantly antagonized by IP
Figure 2. The effects of NPW30 microinjected into the RVM
(phase 1: p> 0.05, phase 2: p< 0.001). IP naloxone and IT
WAY100135 significantly antagonized the effect of NPW30 and IT
prazosin. IT idazoxan and IT SB269970 significantly enhanced the
analgesic effect of NPW30. Ordinate: number of flinches per min;
abscissa: time after drug administration (min). Figure 3. The effects of NPW30 microinjected into the ipsilateral
LC decreased the phase 1 (p< 0.005) and phase 2 (p< 0.001)
responses. IP naloxone, IT idazoxan, IT WAY100135 antagonized
the phase 2 depressant effect of NPW30. IT idazoxan significantly
enhanced the phase 1 analgesic effect of NPW30 and antagonized
the phase 2 effect. IT prazosin and IT SB269970 significantly
enhanced the phase 2 analgesic effect of NPW30. Ordinate:
number of flinches per min; abscissa: time after drug administration
(min).
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naloxone (n¼ 8, p< 0.001), IT idazoxan (n¼ 8,
p< 0.001), IT WAY100135 (p< 0.001), and IT
SB269970 (n¼ 5, p< 0.001).
Discussion
In the present study, NPW30 was microinjected into the
RVM, ipsilateral LC, contralateral LC, ipsilateral PAG,
and contralateral PAG. NPW30 was found to decrease
the instances of flinching behavior induced by paw for-
malin injection. This suggests that NPW30 injected into
the RVM, ipsilateral LC, contralateral LC, ipsilateral
PAG, and contralateral PAG produced an analgesic
effect on inflammatory pain. All these analgesic effects
of NPW30 were antagonized by IP naloxone, suggesting
that the NPW30 induced analgesic effect was, at least
partly, mediated by opioidergic mechanisms. On the
other hand, IT prazosin, an a-1 adrenergic receptor
antagonist, and/or IT idazoxan, an a-2 adrenergic recep-
tor antagonist, sometimes antagonized NPW30 induced
Figure 4. The effects of NPW30 microinjected into the contra-
lateral LC decreased the phase 1 (p< 0.001) and phase 2
(p< 0.001) responses. IP naloxone and IT SB269970 significantly
antagonized the phase 1 and phase 2 responses. IT prazosin and IT
idazoxan antagonized the phase 2 effect of NPW30. Ordinate:
number of flinches per min; abscissa: time after drug administration
(min).
Figure 5. The effects of NPW30 microinjected into the ipsilateral
PAG decreased the phase 1 (p< 0.05) and phase 2 (p< 0.001)
responses. IT WAY100135 significantly antagonized the phase 1
and phase 2 responses. IP naloxone, IT idazoxan, and IT SB269970
significantly antagonized the phase 2 depressant effect. Ordinate:
number of flinches per min; abscissa: time after drug administration
(min).
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analgesia and, at other times, enhanced NPW30 induced
analgesia or had no effect on NPW30 induced analgesia.
These findings suggest that when NPW30 is injected into
the RVM, ipsilateral LC, contralateral LC, ipsilateral
PAG, and contralateral PAG, activation of a spinal
a-1 adrenergic receptor and spinal a-2 adrenergic recep-
tor occurs, producing either a pronociceptive effect or
anti-nociceptive effect. In some cases, NPW30 did not
activate a spinal a-1 adrenergic receptor or spinal a-2
adrenergic receptor. The effects of 5-HT antagonists
on NPW30 induced analgesia were almost the same as
those of the a-1 and a-2 antagonists. IT WAY100135, a
5-HT1A receptor antagonist, and IT SB269970, a 5-HT7
receptor antagonist, also sometimes antagonized
NPW30 induced analgesia and, at other times, enhanced
NPW30 induced analgesia or had no effect on NPW30
induced analgesia.
Doses of drugs and timing of injection. As described in the
Methods section, the doses of NPW30, antagonists, and
injection timing were determined according to prelimi-
nary studies or previous reports. We found that IP nal-
oxone, IT prazosin, IT idazoxan, IT WAY100135, and
IT SB269970 at the doses used in this study antagonized
the effect of NPW30 on phase 1 and/or phase 2
responses. These data suggest that the injected doses
and the injection timing in this study were adequate to
examine the analgesic mechanisms of NPW30.
Injection site in RVM, LC, and PAG. As shown in Figure 1,
NPW30 was injected into the intended site in RVM, LC,
and PAG. The PAG injection site is within the lateral
part of the PAG. It has been reported that predominant
Fos expression evoked by thermal noxious stimulation
was observed in the lateral PAG.18 Neurons in the dor-
solateral/lateral columns of the PAG mediate active
coping strategies that include anti-nociception associated
with sympathoexcitation.19 Thus, we believe that lateral
PAG was involved in nociceptive modulation and that
our PAG injection site was adequate to investigate the
role of NPW30 in the PAG.
Role of opioidergic mechanisms on spinal nociceptive
transmission. It has been suggested that gamma-
aminobutyric acid (GABA) disinhibition in the RVM
stimulates the opioidergic descending analgesic
system.20 In the RVM, microinjection of NPW30 may
disinhibit the GABAergic system and activate opioid
systems.
It has been reported that LC-mediated descending
noradrenergic modulation is implicated in the analgesic
mechanisms of opioids.21–23 Thus, it is possible that
modulation of LC activity by NPW30 may activate the
opioidergic analgesic system.
It has been reported that morphine microinjection
into the PAG produces an analgesic effect and that
this analgesic effect was antagonized by IT a–2 antago-
nist.24 Moreover, PAG electrical stimulation-induced
inhibition of nociceptive dorsal horn neurons in rats is
associated with the release of noradrenaline.25 These
Figure 6. The effects of NPW30 microinjected into the contra-
lateral PAG decreased the phase 1 (p< 0.05) and phase 2
(p< 0.001) responses. IT WAY100135 significantly antagonized the
phase 1 and phase 2 responses. IP naloxone, IT idazoxan, and IT
SB269970 significantly antagonized the phase 2 depressant effect.
Ordinate: number of flinches per min; abscissa: time after drug
administration (min).
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findings suggest that NPW30 microinjected into both the
ipsilateral and contralateral PAG activated the opioider-
gic system in the PAG and increased spinal noradrena-
line release. In this study, the analgesic effect of NPW30
microinjected into the ipsilateral and contralateral PAG
was antagonized by both IP naloxone and IT idazoxan.
Role of noradrenaline receptor-mediated mechanisms on spinal
nociceptive transmission. Noradrenaline has been reported
to play an important role in the descending pain inhib-
itory system. The source of noradrenaline was LC, and
noradrenaline was released in the spinal cord. Released
noradrenaline in the spinal cord acts on a–2 receptors on
the neuron to produce an analgesic effect.26 It has been
reported that the activation of a–2 receptors is generally
associated with a suppression of neuronal activity in the
dorsal horn.27 On the other hand, activation of a–1
receptors exerted a robust excitatory influence upon
the neuronal activity, and the a–1 receptor in the
dorsal horn has been reported to have both pronocicep-
tive and anti-nociceptive roles.27
During phase 1, IT prazosin did not affect NPW30
induced analgesia. IT idazoxan enhanced
NPW30-induced analgesia in ipsilateral LC studies, but
not in other studies. This suggests that during phase 1,
NPW30 microinjection into the ipsilateral LC induced nor-
adrenaline release and produced a pronociceptive effect.
During phase 2, IT idazoxan antagonized the
NPW30-induced analgesia in the ipsilateral LC, contra-
lateral LC, ipsilateral PAG, and contralateral PAG stud-
ies and enhanced in the RVM study. IT prazosin
antagonized NPW30 induced analgesia in the contralat-
eral LC study and enhanced NPW30 induced analgesia
in the RVM and ipsilateral LC studies. Thus, during
phase 2, noradrenaline activated both the a-1 and a–2
receptors and produced pronociceptive and anti-
nociceptive effects. It has been reported that when nor-
adrenaline acts on the spinal astrocytes in superficial
laminae, noradrenaline produces nociceptive effects by
activating the a–1 receptor.28 The mechanisms of how
a–2 receptor activation produces a pronociceptive effect
is not yet fully understood. However, our data strongly
suggests that spinal noradrenaline produces a pronoci-
ceptive effect depending on the situation.
Role of 5-HT receptor-mediated mechanisms on spinal nocicep-
tive transmission. 5-HT has been known to have complex
pain modulatory roles in the spinal cord, such as prono-
ciceptive and anti-nociceptive effects.27,29 For example,
low doses of IT 5-HT were found to produce an analge-
sic effect, whereas larger doses of IT 5-HT were found to
induce a pronociceptive effect.30 Moreover, either a 5-
HT1A receptor agonist or 5-HT7 receptor agonist pro-
duced both pronociceptive and anti-nociceptive
effects.29,31 In the present study, WAY100135, a
5-HT1A receptor antagonist, and SB269970, a 5-HT7
receptor antagonist, were used to clarify the role of the
5-HT receptor-mediated mechanism on NPW30 induced
analgesia.
5-HT input to the spinal cord arose from the nucleus
raphe magnus (NRM), and NRM was one of the nuclei
composed of RVM.27 In the RVM study during phase 2,
WAY100135 antagonized the analgesic effect of NPW30
and SB269970 enhanced the analgesic effect of NPW30.
These data strongly suggest that, in the RVM study, 5-
HT1A receptor activation induced an anti-nociceptive
effect, and 5-HT7 receptor activation produced a prono-
ciceptive effect.
Electric stimulation of PAG and NRM had been
reported to produce 5-HT mediated analgesia, and
PAG was known to be another source of 5-HT.27 In
the ipsilateral and contralateral PAG study, either
WAY100135 or SB269970 antagonized the analgesic
effect of NPW30. These findings suggest that NPW30
microinjections into the PAG activated 5-HT1A and
5-HT7 receptors in the spinal cord, resulting in an anal-
gesic effect.
Although the direct relationship between LC and
spinal 5-HT was unclear, WAY100135 antagonized the
analgesic effect of NPW30 in the ipsilateral LC study.
SB269970 enhanced the analgesic effect of NPW30 in the
ipsilateral LC study and antagonized the analgesic effect
of NPW30 in the contralateral LC study. These data
strongly suggest that NPW30 microinjected into the
LC produced spinal 5-HT1A and 5-HT7 receptor-
mediated nociceptive modulation.
Conclusion
Our findings strongly indicate that NPBW1/NPBW2
and the NPW system are involved in the descending
pain modulatory system. NPW30 microinjection into
the RVM, LC, and PAG modulated noradrenaline and
5-HT mediated nociceptive transmission in the spinal
cord and produced a pronociceptive and anti-
nociceptive effect depending on the situation.
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